Neumora Therapeutics is a clinical-stage biotechnology company integrating data science and neuroscience to develop precision medicines for neuropsychiatric and neurodegenerative disorders. The company is advancing a data-driven precision neuroscience platform and patient enrichment strategies intended to cut through brain disease heterogeneity and better match patients to targeted therapeutics. Its pipeline includes seven development programs spanning clinical and preclinical stages, with a mix of clinically validated and novel approaches. Neumora recently completed enrollment in a Phase 2a trial for NMRA-140, and is progressing clinical-stage NMRA-511 and NMRA-266 toward Phase 1 initiation in 2023; earlier-stage programs target Parkinson’s disease and ALS. The company says the financing and prior capital give it a very strong financial position to advance multiple near-term, value-creating milestones. Neumora has operations in the Greater Boston Area and South San Francisco. Neumora builds a scalable precision data science platform that integrates genomics, imaging, EEG, digital and clinical data to define patient subtypes via Data Biopsy Signatures™ and Precision Phenotypes™. The company’s core product approach is to match targeted therapeutics to enriched patient populations to de-risk trials and improve probability of success. Neumora has assembled a pipeline of eight clinical, preclinical and discovery-stage programs sourced from internal discovery, acquisitions of private companies and license agreements with Amgen. The company says it was launched to transform neuroscience R&D away from broad symptom-based classifications toward mechanism-driven precision medicines. Neumora plans to advance its portfolio across neuropsychiatric and neurodegenerative diseases using its neural-network toolbox and multi-modal datasets. Financially, Neumora has raised over $500 million, including a separately announced $100 million equity investment from Amgen, and operates in the Greater Boston Area and South San Francisco.

Total raised

$212M

Funding rounds

2

Latest round

Series B

Latest activity

Oct 2022